HI
LJPC

HBK Investments’s La Jolla Pharmaceutical Company LJPC Stock Holding History

HBK Investments’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,500
Closed -$672K – 1106
2017
Q1 		$672K Buy
+22,500
New +$574K 0.01% 474

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

HBK Investments's LJPC Position: Q2 2017 in Review

HBK Investments sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2017, closing a stake of 22,500 shares — an estimated $672K sold.

HBK Investments first reported a position in LJPC in Q1 2017 and held it in 1 quarter. The position peaked at $672K in Q1 2017. 83 funds tracked by Wall St. Rank hold LJPC as of Q2 2017.

  • HBK Investments reported no remaining La Jolla Pharmaceutical Company position as of Q2 2017 after selling out during the quarter.
  • HBK Investments sold 22,500 La Jolla Pharmaceutical Company shares in Q2 2017, an estimated $672K.
  • HBK Investments first reported a position in La Jolla Pharmaceutical Company in Q1 2017 and held it in 1 quarter.
  • HBK Investments's La Jolla Pharmaceutical Company position peaked at $672K in Q1 2017.
  • 83 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2017.

Based on HBK Investments's 13F filing for Q2 2017, filed 14 Aug 2017.